Targeting USP5 offers a potential therapeutic strategy for p53-related melanoma, and, in combination with current therapeutic strategies, it alters cell growth and cell cycle distribution associated with p21 induction in melanoma cells. The gene discussed is USP5; the disease is melanoma.